Navigation Links
SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO

SAN MATEO, CA — April 27, 2007 — SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the following abstracts have been accepted for the Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois on June 1-5, 2007:


ZADAXIN® (thymalfasin, thymosin alpha 1) Poster Presentation
A large first-line, randomized, dose-finding, phase II study on Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with or without Interferon alpha (IFN?) vs DTIC plus IFN? in stage IV melanoma. Tumor response and survival results
(ASCO abstract number: 31541)

SCV-07 Abstract Proceedings
Effect of the Immune Modulating Peptide, SCV-07, in the Murine B16 Melanoma Model
(ASCO abstract number: 35151)

For further information about this conference, please visit www.asco.org.

About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C. ZADAXIN is approved for sale in select markets internationally, most notably in China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC BeadTM, currently pending Chinese regulatory approval for the treatment of liver cancer. For the U.S. market, SciClone's clinical-stage drug development candidates are SCV-07 for the treatment of viral infectious diseases and RP101 for the treatment of pancreatic cancer. For more information about SciClone, visit www.sciclone.com.






Page: 1 2

Related medicine technology :

1. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SciClone Announces ZADAXIN and SCV Abstracts Accepted ASCO
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... its catalogue: Global Feminine Hygiene Products Industry ... report analyzes the worldwide markets for Feminine Hygiene Products ... Pads/Towels, Tampons, Panty liners, and Others. The report provides ... , Japan , ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a new ... The Market for Medical Devices in ... European, Middle Eastern and African markets represent significant ... of its coverage, this study: The Market for ... medical device markets and estimates markets for specific ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
Breaking Medicine Technology:Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... Arnold & Itkin LLP has filed five ... on claims that many of the companies, defective devices ... the attorneys at Arnold & Itkin are ... shoulder surgery. The pumps utilize a catheter to deliver continuous doses ...
... , BEDFORD, Mass., Nov. 11 Hologic, Inc. (Nasdaq: ... at the NASDAQ OMX 23rd Investor Program in London on ... parties are invited to listen to a live audio webcast ... company,s website at www.hologic.com/investor . An archive ...
Cached Medicine Technology:Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps 2Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps 3
(Date:8/20/2014)... Thompson HealthDay Reporter WEDNESDAY, ... fell dramatically during the past two decades, plummeting 57 percent ... shows. An estimated 4 million fewer births occurred among ... from the U.S. Centers for Disease Control and Prevention. ... the report," said Bill Albert, chief program officer of The ...
(Date:8/20/2014)... have discovered that the immune system is defective in people ... why sufferers have ongoing issues with pain. , The research ... could also help to explain why some painkillers may not ... affects up to 10% of the community. There are ... gut pain, which often has the greatest impact on sufferers, ...
(Date:8/20/2014)... Pigs, hearts transplanted into baboons survived for more than ... achieved, researchers report. The work is part of ... shorten transplant waiting lists. In this study, scientists ... The genetic engineering and new methods of suppressing the ... to survive for more than a year. The ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... grow may help doctors diagnose and treat the most aggressive ... found that the deadliest skin cancers occur most often on ... history of sun exposure. These lesions also grow quickly ... growth -- called "high mitotic rate" -- is associated ...
(Date:8/20/2014)... Tuberculosis is one of the most persistent and deadliest ... million people each year. , Scientists who study tuberculosis ... tuberculosis likely spread from humans in Africa to seals ... America and transmitted it to Native people there before ... Mycobacterial Genomes Reveal Seals as a Source of New ...
Breaking Medicine News(10 mins):Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Pain treatments less effective for those with irritable bowel 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3
... , , LAS VEGAS, ... assistance program, announced today that it has partnered with the Las Vegas ... have access to the free drug card program. The Chamber has committed ... members to develop additional card distribution sites. , , ...
... YORK, July 28 A record 488 new, innovative ... New York City, according to a new report released today at ... Food and Drug Administration (FDA) or are in human clinical trials. ... Darryl Strawberry, a two-time colon cancer survivor, described his battle against ...
... , , Seniors Group ... Americans , , WASHINGTON, July 28 ... endorsing the plan presented by President Obama and his Congressional allies ... pay for "health care reform." Thair Phillips, the new president of ...
... A new study by psychologists at the University at ... finds that in the aftermath of national trauma, the ... implications for individual well-being and that the kinds of ... psychological outcomes for them. The study, "The Political is ...
... were overcast , TUESDAY, July 28 (HealthDay News) -- A ... and other cognitive problems in people suffering from depression. , ... shift with shifting skies, with more depression linked with less ... exposure and cognition have been paired, stated the authors of ...
... TSX: COM, , , VANCOUVER, July 28 /PRNewswire-FirstCall/ ... announced that it has earned a US$15 million milestone payment ... an affiliate. The milestone was triggered by the submission, by ... Medicines Agency (EMEA) seeking marketing approval for vernakalant (iv) in ...
Cached Medicine News:Health News:Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 2Health News:Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 3Health News:Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 4Health News:RetireSafe Blasts AARP for Supporting Plan to Pay for Health Care on the Backs of Seniors 2Health News:Stories we tell about national trauma reflect our psychological well-being 2Health News:Stories we tell about national trauma reflect our psychological well-being 3Health News:Gloomy Days Dim Cognitive Powers of the Depressed 2Health News:Cardiome Achieves Milestone From Collaboration With Merck Co., Inc. 2Health News:Cardiome Achieves Milestone From Collaboration With Merck Co., Inc. 3
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: